Neurolixis launched a collaboration with the GALA® laboratory in Castres, France. GALA® is a platform of the Rapsodee/IMT Mines Albi research facility specialized in galenic formulation. GALA® has experimental tools and skills in process engineering, formulation and advanced galenics (encapsulation, vectorization, development of innovative galenic forms).
The Neurolixis-GALA collaboration focuses on the development of a novel formulation of NLX-112. This compound is in clinical development for treatment of dyskinesia (abnormal movements) seen in patients suffering from Parkinson's disease. The new formulation of NLX-112 will optimize its anti-dyskinetic activity and facilitate its administration to patients. The development of NLX-112 has been supported by grants from the Michael J. Fox Foundation, (USA) and Parkinson's UK. The Neurolixis-GALA collaboration is financed by subsidies from the Occitanie Region in France.
Adrian Newman-Tancredi, PhD, DSc, Chief Scientific Officer of Neurolixis, commented: "The development of a novel galenic formulation of NLX-112 will be strong asset for the project and enable Parkinson’s disease patients (about 1 million in the USA) to maximally benefit from this innovative treatment.”